Abstract：
Increased incidence of breast cancer has stimulated development of new diagnostic and therapeutic methods. The programmed cell death 1 (PD1) pathway and its inhibitors are promising avenues for investigation. PD1 includes PD ligands 1 (PDL1) and 2 (PDL2). We investigated the expression of PD1 and PDL1 in invasive breast carcinomas using immunohistochemical staining. We used 171 invasive breast carcinoma specimens from which tissue microarray blocks were created. Immunohistochemical staining of PD1 using NAT105, and PDL1 using CAL10 was performed on tissue microarray sections. NAT105 and CAL10 are useful clones for detecting expression of PD1 and PDL1. PD1 and PDL1 immunostaining was significantly stronger in carcinomas with basal-like phenotype compared to other molecular breast cancer types. PD1 and PDL1 expression also was associated with a high histologic grade and a high Ki-67 index. PD1 expression also was associated with lymphovascular invasion and axillary metastasis. PD1 and PDL1 expression is associated with aggressive tumor behavior and a basal-like phenotype in breast cancer. We suggest that inhibition of the PD1/PDL1 pathway, particularly in triple negative breast carcinomas with basal-like phenotype, might be useful for targeted immunotherapy.
摘要：
乳腺癌发病率的增加刺激了新的诊断和治疗方法的发展。程序性细胞死亡1（PD1）途径及其抑制剂是有希望的研究途径。PD1包括PD配体1(PDL1)和2(PDL2)。我们使用免疫组织化学染色研究了浸润性乳腺癌中PD1和PDL1的表达。我们使用了171个浸润性乳腺癌标本，从中创建了组织微阵列块。在组织微阵列切片上进行使用NAT105的PD1和使用CAL10的PDL1的免疫组织化学染色。NAT105和CAL10是检测PD1和PDL1表达的有用克隆。与其他分子乳腺癌类型相比，具有基底样表型的癌的PD1和PDL1免疫染色明显更强。PD1和PDL1的表达也与高组织学分级和高Ki-67指数相关。PD1的表达也与淋巴管浸润和腋窝转移有关。PD1和PDL1表达与乳腺癌侵袭性肿瘤行为和基底样表型相关。我们建议抑制PD1/PDL1通路，特别是在具有基底样表型的三阴性乳腺癌中，可能对靶向免疫疗法有用。
